Shandong Buchang Pharmaceuticals Co., Ltd. (603858.SH) Latest Company News

Sep 15, 2026, 08:00 UTC
Shandong Buchang Pharmaceuticals' controlling subsidiary Beijing Hepu Jingyuan Medical Technology obtained a renewed Medical Device Business License from the Beijing Huairou District Market Supervision Administration, with changes limited to domicile, business premises and warehouse addresses.
Source:
- finance.sina.cn
Aug 28, 2026, 07:35 UTC
Stepun Pharmaceutical's wholly-owned subsidiary Baoding Tianhao Pharmaceutical received a drug registration certificate from China's National Medical Products Administration for terbinafine hydrochloride spray, a Class 4 chemical OTC drug for treating fungal skin infections.
Source:
- finance.sina.cn
Aug 27, 2026, 10:17 UTC
Step Pharmaceutical announced its first-half 2026 results, with revenue of 5.003 billion yuan, down 11.67% year-on-year, and net profit of 503 million yuan, down 19.93% year-on-year.
Source:
- finance.sina.cn
Aug 17, 2026, 11:50 UTC
Shandong Buchang Pharmaceutical Co., Ltd. and Professor Zhao Buchang, as the first completing unit and first completer, were awarded the First Prize of the 2025 Shandong Province Science and Technology Progress Award for their project on digital-intelligent technology for the whole traditional Chinese medicine industry chain.
Source:
- wap.eastmoney.com
Aug 17, 2026, 09:16 UTC
Step Pharmaceutical's controlled subsidiary Beijing Boyuan Runbu Pharmaceutical R&D Co., Ltd. received acceptance from China's National Medical Products Administration for its clinical trial application for the drug BC923 injection, a Class 1 chemical drug for hypertension.
Source:
- finance.sina.cn

603858.SH

Shandong Buchang Pharmaceuticals' controlling subsidiary Beijing Hepu Jingyuan Medical Technology obtained a renewed Medical Device Business License from the Beijing Huairou District Market Supervision Administration, with changes limited to domicile, business premises and warehouse addresses.

Stepun Pharmaceutical's wholly-owned subsidiary Baoding Tianhao Pharmaceutical received a drug registration certificate from China's National Medical Products Administration for terbinafine hydrochloride spray, a Class 4 chemical OTC drug for treating fungal skin infections.

Step Pharmaceutical announced its first-half 2026 results, with revenue of 5.003 billion yuan, down 11.67% year-on-year, and net profit of 503 million yuan, down 19.93% year-on-year.

Step Pharmaceutical's controlled subsidiary Beijing Boyuan Runbu Pharmaceutical R&D Co., Ltd. received acceptance from China's National Medical Products Administration for its clinical trial application for the drug BC923 injection, a Class 1 chemical drug for hypertension.